Rezvan Mohammadi, Sepideh Ghani, Roghaye Arezumand, Shohreh Farhadi, Yalda Khazaee-poul, Bahram Kazemi, Fatemeh Yarian*, Somaye Noruzi, Abbas Alibakhshi, Mahsa Jalili and Shahin Aghamiri Pages 1 - 19 ( 19 )
The application of monoclonal antibodies and antibody fragments with the advent of recombinant antibody technology has made notable progress in clinical trials to provide a regulated drug release and extra targeting to the special conditions in the function site. Modification of antibodies has facilitated using mAbs and antibody fragments in numerous models of therapeutic and detection utilizations, such as stimuliresponsive systems. Antibodies and antibody derivatives conjugated with diverse stimuliresponsive materials have been constructed for drug delivery in response to a wide range of endogenous (electric, magnetic, light, radiation, ultrasound) and exogenous (temperature, pH, redox potential, enzymes) stimuli. In this report, we highlighted the recent progress on antibody-conjugated stimuli-responsive and dual/multi-responsive systems that affect modern medicine by improving a multitude of diagnostic and treatment strategies.
Antibody, derivatives of antibody, endogenous stimuli, exogenous stimuli, stimulus-responsive systems, targeted delivery of antibody.